These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 16916451)
1. Nociceptors in cardiovascular functions: complex interplay as a result of cyclooxygenase inhibition. Premkumar LS; Raisinghani M Mol Pain; 2006 Aug; 2():26. PubMed ID: 16916451 [TBL] [Abstract][Full Text] [Related]
2. Dual acting anti-inflammatory drugs: a reappraisal. Bertolini A; Ottani A; Sandrini M Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348 [TBL] [Abstract][Full Text] [Related]
3. Iloprost-induced nociception: determination of the site of anti-nociceptive action of cyclooxygenase inhibitors and the involvement of cyclooxygenase products in central mechanisms of nociception. Ayoub SS; Botting RM Methods Mol Biol; 2010; 644():207-15. PubMed ID: 20645177 [TBL] [Abstract][Full Text] [Related]
4. [The role of cyclooxygenase and prostaglandins in the pathogenesis of rheumatoid arthritis]. Stańczyk J; Kowalski ML Pol Merkur Lekarski; 2001 Nov; 11(65):438-43. PubMed ID: 11852819 [TBL] [Abstract][Full Text] [Related]
5. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Burian M; Geisslinger G Pharmacol Ther; 2005 Aug; 107(2):139-54. PubMed ID: 15993252 [TBL] [Abstract][Full Text] [Related]
6. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562 [TBL] [Abstract][Full Text] [Related]
7. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. Qi Z; Hao CM; Langenbach RI; Breyer RM; Redha R; Morrow JD; Breyer MD J Clin Invest; 2002 Jul; 110(1):61-9. PubMed ID: 12093889 [TBL] [Abstract][Full Text] [Related]
8. Paracetamol (Acetaminophen): mechanisms of action. Anderson BJ Paediatr Anaesth; 2008 Oct; 18(10):915-21. PubMed ID: 18811827 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818 [TBL] [Abstract][Full Text] [Related]
10. Differentiation of cyclooxygenase 1- and 2-derived prostanoids in mouse kidney and aorta. Qi Z; Cai H; Morrow JD; Breyer MD Hypertension; 2006 Aug; 48(2):323-8. PubMed ID: 16801485 [TBL] [Abstract][Full Text] [Related]
11. Rutaecarpine, a quinazolinocarboline alkaloid, inhibits prostaglandin production in RAW264.7 macrophages. Woo HG; Lee CH; Noh MS; Lee JJ; Jung YS; Baik EJ; Moon CH; Lee SH Planta Med; 2001 Aug; 67(6):505-9. PubMed ID: 11509968 [TBL] [Abstract][Full Text] [Related]
12. Dynamics of different arachidonic acid orientations bound to prostaglandin endoperoxide synthases. Sachett LG; Verli H Eur J Med Chem; 2011 Oct; 46(10):5212-7. PubMed ID: 21864948 [TBL] [Abstract][Full Text] [Related]